Aaron is a founder and Managing Partner of Scion. He has spent over a decade specializing in founding, building and investing in life sciences companies, focusing primarily on therapeutics. Aaron currently serves as a board member of Tourmaline Bio (NASDAQ: TRML), where he has been serving since the company’s inception. Previously, he was a Venture Partner at Medicxi, where he was a founding board member of Centessa Pharmaceuticals PLC (NASDAQ: CNTA) and assisted the team with other privately held therapeutics investments. Before joining Medicxi, he was a co-founder and founding board member of RayzeBio (NASDAQ: RYZB), which was recently acquired by Bristol Myers Squibb (NYSE: BMY).
From 2011 until 2019, Aaron was a Partner at Apple Tree Partners (ATP), a life sciences venture capital firm. At ATP, Aaron was a key member of the therapeutics investment practice, playing a leading role in assembling several ATP portfolio companies, and most notably, serving on the boards of Akero Therapeutics (NASDAQ: AKRO), Corvidia Therapeutics (acquired by Novo Nordisk) and Syntimmune (acquired by Alexion), as well as two privately held companies (Marengo and Ascidian). During his time at ATP, Aaron was also a board observer at Stoke Therapeutics (NASDAQ: STOK) and led many of ATP’s crossover and public biotech investments. Before joining ATP in 2011, Aaron held various roles in private equity and investment banking.
Aaron received a B.S. in Finance and International Business from NYU Stern’s School of Business.
What is Aaron Kantoff's net worth?
The estimated net worth of Aaron Kantoff is at least $2.18 million as of October 24th, 2023. Kantoff owns 45,391 shares of Tourmaline Bio stock worth more than $2,177,860 as of December 5th. This net worth estimate does not reflect any other investments that Kantoff may own. Learn More about Aaron Kantoff's net worth.
How do I contact Aaron Kantoff?
Has Aaron Kantoff been buying or selling shares of Tourmaline Bio?
Aaron Kantoff has not been actively trading shares of Tourmaline Bio within the last three months. Most recently, on Tuesday, October 24th, Aaron Kantoff bought 7,500 shares of Tourmaline Bio stock. The stock was acquired at an average cost of $11.86 per share, with a total value of $88,950.00. Following the completion of the transaction, the director now directly owns 45,391 shares of the company's stock, valued at $538,337.26. Learn More on Aaron Kantoff's trading history.
